248 related articles for article (PubMed ID: 32272129)
1. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease.
Napier TC; Kirby A; Persons AL
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Aug; 102():109942. PubMed ID: 32272129
[TBL] [Abstract][Full Text] [Related]
2. Nigrostriatal and Mesolimbic D
Stark AJ; Smith CT; Lin YC; Petersen KJ; Trujillo P; van Wouwe NC; Kang H; Donahue MJ; Kessler RM; Zald DH; Claassen DO
J Neurosci; 2018 Mar; 38(13):3230-3239. PubMed ID: 29483278
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Seeman P
Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
[TBL] [Abstract][Full Text] [Related]
4. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants.
Castro-Martínez XH; García-Ruiz PJ; Martínez-García C; Martínez-Castrillo JC; Vela L; Mata M; Martínez-Torres I; Feliz-Feliz C; Palau F; Hoenicka J
Parkinsonism Relat Disord; 2018 Apr; 49():100-103. PubMed ID: 29361389
[TBL] [Abstract][Full Text] [Related]
5. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
[TBL] [Abstract][Full Text] [Related]
6. Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.
Engeln M; Ansquer S; Dugast E; Bezard E; Belin D; Fernagut PO
Neuropharmacology; 2016 Oct; 109():69-77. PubMed ID: 27216859
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 agonists in the treatment of Parkinson's disease.
Das B; Modi G; Dutta A
Curr Top Med Chem; 2015; 15(10):908-26. PubMed ID: 25832718
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological insights into impulsive-compulsive spectrum disorders associated with dopaminergic therapy.
Napier TC; Persons AL
Eur J Neurosci; 2019 Aug; 50(3):2492-2502. PubMed ID: 30269390
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical studies of pramipexole: clinical relevance.
Hubble JP
Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
[TBL] [Abstract][Full Text] [Related]
10. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
11. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
Millan MJ
Pharmacol Ther; 2010 Nov; 128(2):229-73. PubMed ID: 20600305
[TBL] [Abstract][Full Text] [Related]
12. Chronic D
Tremblay M; Silveira MM; Kaur S; Hosking JG; Adams WK; Baunez C; Winstanley CA
Eur J Neurosci; 2017 Jan; 45(1):159-166. PubMed ID: 27422144
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
Rascol O
J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
[TBL] [Abstract][Full Text] [Related]
14. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
16. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?
Magnard R; Vachez Y; Carcenac C; Krack P; David O; Savasta M; Boulet S; Carnicella S
Transl Psychiatry; 2016 Mar; 6(3):e753. PubMed ID: 26954980
[TBL] [Abstract][Full Text] [Related]
17. New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.
Grassi G; Albani G; Terenzi F; Razzolini L; Ramat S
Neurol Sci; 2021 Jul; 42(7):2673-2682. PubMed ID: 33852081
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
19. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
20. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
